Humanin research spans more than two decades.

Humanin has one of the more complex mechanism stories in the peptide world. It does not act on a single receptor with a single downstream effect.

Humanin dosing in clinical practice is largely empirical. There is no published phase 2 dose finding study in humans for any indication.

Introduction Humanin was the first identified mitochondrial derived peptide, reported by Hashimoto and colleagues in 2001 from a cDNA library of neurons that survived…

Humana’s business is heavily Medicare-weighted, which puts Zepbound in a tough spot on Part D plans.

Introduction Humana’s book of business is heavily weighted toward Medicare Advantage and Medicare Part D, which means most Humana Wegovy® denials hit the same…

Zepbound does not need a chemical taper. There is no withdrawal syndrome, no receptor downregulation that has to be unwound slowly.

Wegovy does not require a chemical taper. There is no withdrawal syndrome and no receptor adaptation that needs slow downregulation.

Ozempic does not require a chemical taper.